Usually, research takes time and patience — here are some tips for cultivating patience. Graphic by Miguel Tovar/University of Houston

Aristotle, one of the most famous philosophers and scientists of all time, once said, "Patience is bitter, but its fruit is sweet."

What the phrase conveys is all too familiar to those in the scientific community. Patience needs to be cultivated by researchers who wait for the outcome of their studies. History is full of success stories of the science community showing both patience and persistence.

Quitters never prosper

Patience is essentially the ability to stay relatively unruffled in the face of adversity. Earning a Ph.D. takes time, writing grants and getting funding takes time, and experiments – some of them never yield results or take a long time to do so.

For example, there is the story of the two scientists who discovered the HPV virology, which eventually led to routine tests that check for cervical cancer in women. They were studying and researching the bacteria that causes the HPV virus for nearly 13 years before their findings were accepted. "In January 1928, Dr. George N. Papanicolaou first announced his findings at the Third Race Betterment Conference in Battle Creek, Michigan, but these were met with skepticism and resistance from the scientific community. This rejection did not deter Dr. Papanicolaou from continuing his research in this field in 1939, until eventually his findings were published on March 11, 1941," wrote Ioannis N. Mammas and Demetrios A. Spandidos in Experimental and Therapeutic Medicine.

This is by no means the only example – many researchers face setbacks and long experimentation periods that seemingly go nowhere, making any outcome at all even more sacred.

A marshmallow now…

A new study by Adrianna Jenkins, a UC Berkeley postdoctoral researcher, and Ming Hsu, an associate professor of marketing and neuroscience at UC Berkeley's Haas School of Business, is making headway in determining whether willpower is actually the way one overcomes adversity or if patience is born of something else. We know the famous marshmallow test, where young children were told they could have one marshmallow right away or two marshmallows if they waited a short time. Thirty years later, the children with better impulse control were more successful than their counterparts who had little self-control.

The newer study works like this: "The actual reward outcomes were identical, but the way they were framed differed. For example, under an "independent" frame, a participant could receive $100 tomorrow or $120 in 30 days. Under a "sequence" frame, a participant had to decide whether to receive $100 tomorrow and no money in 30 days or no money tomorrow and $120 in 30 days." More on this later.

As one might guess, the ones who showed delayed gratification were the ones using their imaginations the most: "Participants in the sequence frame reported imagining the consequences of their choices more than those in the independent frame. One participant wrote, 'It would be nice to have the $100 now, but $20 more at the end of the month is probably worth it because this is like one week's gas money.''

Willing yourself patient?

So how does willpower play into the equation? "Whereas willpower might enable people to override impulses, imagining the consequences of their choices might change the impulses," Jenkins says. "People tend to pay attention to what is in their immediate vicinity, but there are benefits to imagining the possible consequences of their choices."

Researchers may not think of themselves as particularly creative, but an imagination is definitely needed to frame hypotheses and conduct experiments, so one could argue that scientists are perhaps some of the most creative, imaginative people around.

The Big Idea

Waiting is still a drag, right?

In The Greater Good, a University of California – Berkeley science magazine, there were three concrete steps to help your research become even more fulfilling and make you more patient as an investigator: mindfulness, reframing the situation and being grateful.

First, mindfulness. Mindfulness techniques include things as simple as acknowledging you are overwhelmed or frustrated with a co-PI. It lets you deal better and leads to the second step, which is reframing the situation in a positive light. And, remember the $120 scenario? Those who were grateful for the amount of money they were receiving did better at delaying gratification, according to the study.

So, when you're working on your latest research, don't forget to practice patience. The fruits will taste even sweeter once the obstacles are endured, one by one.

------

This article originally appeared on the University of Houston's The Big Idea. Sarah Hill, the author of this piece, is the communications manager for the UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Texas tops ranking of best state for investors in new report

by the numbers

Texas ranks third on a new list of the best states for investors and startups.

Investment platform BrokerChooser weighed five factors to come up with its ranking:

  • 2024 Google search volume for terms related to investing
  • Number of investors
  • Number of businesses receiving investments in 2024
  • Total amount of capital invested in businesses in 2024
  • Percentage change in amount of investment from 2019 to 2024

Based on those figures, provided mostly by Crunchbase, Texas sits at No. 3 on the list, behind No. 1 California and No. 2 New York.

Especially noteworthy for Texas is its investment total for 2024: more than $164.5 billion. From 2019 to 2024, the state saw a 440 percent jump in business investments, according to BrokerChooser. The same percentages are 204 percent for California and 396 percent for New York.

“There is definitely development and diversification in the American investment landscape, with impressive growth in areas that used to fly under the radar,” says Adam Nasli, head analyst at BrokerChooser.

According to Crunchbase, funding for Texas startups is off to a strong start in 2025. In the first three months of this year, venture capital investors poured nearly $2.9 billion into Lone Star State companies, Crunchbase data shows. Crunchbase attributes that healthy dollar amount to “enthusiasm around cybersecurity, defense tech, robotics, and de-extincting mammoths.”

During the first quarter of this year, roughly two-thirds of VC funding in Texas went to just five companies, says Crunchbase. Those companies are Austin-based Apptronik, Austin-based Colossal Biosciences, Dallas-based Island, Austin-based NinjaOne, and Austin-based Saronic.

Autonomous truck company rolls out driverless Houston-Dallas route

up and running

Houston is helping drive the evolution of self-driving freight trucks.

In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27.

Close to half of all truck freight in Texas moves along I-45 between Houston and Dallas.

“Now, we are the first company to successfully and safely operate a commercial driverless trucking service on public roads. Riding in the back seat for our inaugural trip was an honor of a lifetime – the Aurora Driver performed perfectly and it’s a moment I’ll never forget,” Chris Urmson, CEO and co-founder of Pittsburgh-based Aurora, said in a news release.

Aurora produces software that controls autonomous vehicles and is known for its flagship product, the Aurora Driver. The software is installed in Volvo and Paccar trucks, the latter of which includes brands like Kenworth and Peterbilt.

Aurora previously hauled more than 75 loads per week under the supervision of vehicle operators from Houston to Dallas and Fort Worth to El Paso for customers in its pilot project, including FedEx, Uber Freight and Werner. To date, it has completed over 1,200 miles without a driver.

The company launched its new Houston to Dallas route with customers Uber Freight and Hirschbach Motor Lines, which ran supervised commercial pilots with Aurora.

“Transforming an old school industry like trucking is never easy, but we can’t ignore the safety and efficiency benefits this technology can deliver. Autonomous trucks aren’t just going to help grow our business – they’re also going to give our drivers better lives by handling the lengthier and less desirable routes,” Richard Stocking, CEO of Hirschbach Motor Lines, added in the statement.

The company plans to expand its service to El Paso and Phoenix by the end of 2025.

“These new, autonomous semis on the I-45 corridor will efficiently move products, create jobs, and help make our roadways safer,” Gov. Greg Abbott added in the release. “Texas offers businesses the freedom to succeed, and the Aurora Driver will further spur economic growth and job creation in Texas. Together through innovation, we will build a stronger, more prosperous Texas for generations.”

In July, Aurora said it raised $820 million in capital to fuel its growth—growth that’s being accompanied by scrutiny.

In light of recent controversies surrounding self-driving vehicles, the International Brotherhood of Teamsters, whose union members include over-the-road truckers, recently sent a letter to Lt. Gov. Dan Patrick calling for a ban on autonomous vehicles in Texas.

“The Teamsters believe that a human operator is needed in every vehicle—and that goes beyond partisan politics,” the letter states. “State legislators have a solemn duty in this matter to keep dangerous autonomous vehicles off our streets and keep Texans safe. Autonomous vehicles are not ready for prime time, and we urge you to act before someone in our community gets killed.”

Houston cell therapy company launches second-phase clinical trial

fighting cancer

A Houston cell therapy company has dosed its first patient in a Phase 2 clinical trial. March Biosciences is testing the efficacy of MB-105, a CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma.

Last year, InnovationMap reported that March Biosciences had closed its series A with a $28.4 million raise. Now, the company, co-founded by Sarah Hein, Max Mamonkin and Malcolm Brenner, is ready to enroll a total of 46 patients in its study of people with difficult-to-treat cancer.

The trial will be conducted at cancer centers around the United States, but the first dose took place locally, at The University of Texas MD Anderson Cancer Center. Dr. Swaminathan P. Iyer, a professor in the department of lymphoma/myeloma at MD Anderson, is leading the trial.

“This represents a significant milestone in advancing MB-105 as a potential treatment option for patients with T-cell lymphoma who currently face extremely limited therapeutic choices,” Hein, who serves as CEO, says. “CAR-T therapies have revolutionized the treatment of B-cell lymphomas and leukemias but have not successfully addressed the rarer T-cell lymphomas and leukemias. We are optimistic that this larger trial will further validate MB-105's potential to address the critical unmet needs of these patients and look forward to reporting our first clinical readouts.”

The Phase 1 trial showed promise for MB-105 in terms of both safety and efficacy. That means that potentially concerning side effects, including neurological events and cytokine release above grade 3, were not observed. Those results were published last year, noting lasting remissions.

In January 2025, MB-105 won an orphan drug designation from the FDA. That results in seven years of market exclusivity if the drug is approved, as well as development incentives along the way.

The trial is enrolling its single-arm, two-stage study on ClinicalTrials.gov. For patients with stubborn blood cancers, the drug is providing new hope.